Catalyst Capital Advisors’s AnaptysBio ANAB Stock Holding History

Catalyst Capital Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-70	Closed	-$2K	–	493
2017 Q1	$2K	Buy	+70	New	+$1.63K	﹤0.01%	461

Other funds holding ANAB

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Catalyst Capital Advisors's ANAB Position: Q2 2017 in Review

Catalyst Capital Advisors sold out of AnaptysBio (ANAB) in Q2 2017, closing a stake of 70 shares — an estimated $2K sold.

Catalyst Capital Advisors first reported a position in ANAB in Q1 2017 and held it in 1 quarter. The position peaked at $2K in Q1 2017. 52 funds tracked by Wall St. Rank hold ANAB as of Q2 2017.

Catalyst Capital Advisors reported no remaining AnaptysBio position as of Q2 2017 after selling out during the quarter.
Catalyst Capital Advisors sold 70 AnaptysBio shares in Q2 2017, an estimated $2K.
Catalyst Capital Advisors first reported a position in AnaptysBio in Q1 2017 and held it in 1 quarter.
Catalyst Capital Advisors's AnaptysBio position peaked at $2K in Q1 2017.
52 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2017.

Based on Catalyst Capital Advisors's 13F filing for Q2 2017, filed 2 Aug 2017.